

EAACI 2025
Image

European Academy of Allergy and Clinical Immunology
EACCI 2025
13 - 16 June



Image



Prof Michaela Lucas

Immunologist and immunopathologist, Clinical Professor at the University of Western Australia

Drug Allergy: What's new in 2025?

Drug Allergy: What's new in 2025?

This presentation is intended for non-promotional scientific purposes only and may contain information on products or indications currently under investigation and/or that have not been approved by the regulatory authorities. Any data about non-Novartis products are based on publicly available information at the time of presentation. Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the SmPC or product information approved in your local country. Please note, that recording, reproduction, distribution (including on social media), public communication and/or content modification are not allowed. All content is proprietary to Novartis Pharma AG and subject to copyright protection.



VIDEO

A summary on the latest insights on food allergy clinical practice

A summary on the latest insights on food allergy clinical practice

This presentation is intended for non-promotional scientific purposes only and may contain information on products or indications currently under investigation and/or that have not been approved by the regulatory authorities. Any data about non-Novartis products are based on publicly available information at the time of presentation. Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the SmPC or product information approved in your local country. Please note, that recording, reproduction, distribution (including on social media), public communication and/or content modification are not allowed. All content is proprietary to Novartis Pharma AG and subject to copyright protection.



VIDEO

An overview on latest insights on food allergy research and diagnostics: Part 1

An overview on latest insights on food allergy research and diagnostics

Part 1

This presentation is intended for non-promotional scientific purposes only and may contain information on products or indications currently under investigation and/or that have not been approved by the regulatory authorities. Any data about non-Novartis products are based on publicly available information at the time of presentation. Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the SmPC or product information approved in your local country. Please note, that recording, reproduction, distribution (including on social media), public communication and/or content modification are not allowed. All content is proprietary to Novartis Pharma AG and subject to copyright protection.



VIDEO

An overview on latest insights on food allergy research and diagnostics: Part 2

An overview on latest insights on food allergy research and diagnostics

Part 2

This presentation is intended for non-promotional scientific purposes only and may contain information on products or indications currently under investigation and/or that have not been approved by the regulatory authorities. Any data about non-Novartis products are based on publicly available information at the time of presentation. Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the SmPC or product information approved in your local country. Please note, that recording, reproduction, distribution (including on social media), public communication and/or content modification are not allowed. All content is proprietary to Novartis Pharma AG and subject to copyright protection.



VIDEO

Image



A/Prof Jason Fok

Immunologist & Allergist at Monash University, Melbourne

CSU: an update on latest data of new treatments in the pipeline focusing on Remibrutinib and Barzolvolimab

CSU: an update on latest data of new treatments in the pipeline focussing on Remibrutinib and Barzolvolimab

This presentation is intended for non-promotional scientific purposes only and may contain information on products or indications currently under investigation and/or that have not been approved by the regulatory authorities. Any data about non-Novartis products are based on publicly available information at the time of presentation. Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the SmPC or product information approved in your local country. Please note that recording, reproduction, distribution (including on social media), public communication and/or content modification are not allowed. All content is proprietary to Novartis Pharma AG and subject to copyright protection.



VIDEO

An update on Hereditary angioedema including presented data on the new treatment options, Garadacimab and Donidalorsen

An update on Hereditary angioedema including presented data on the new treatment options, Garadacimab and Donidalorsen

This presentation is intended for non-promotional scientific purposes only and may contain information on products or indications currently under investigation and/or that have not been approved by the regulatory authorities. Any data about non-Novartis products are based on publicly available information at the time of presentation. Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the SmPC or product information approved in your local country. Please note, that recording, reproduction, distribution (including on social media), public communication and/or content modification are not allowed. All content is proprietary to Novartis Pharma AG and subject to copyright protection.



VIDEO

An update on meat and wheat allergies

An update on meat and wheat allergies

This presentation is intended for non-promotional scientific purposes only and may contain information on products or indications currently under investigation and/or that have not been approved by the regulatory authorities. Any data about non-Novartis products are based on publicly available information at the time of presentation. Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the SmPC or product information approved in your local country. Please note, that recording, reproduction, distribution (including on social media), public communication and/or content modification are not allowed. All content is proprietary to Novartis Pharma AG and subject to copyright protection.



VIDEO

Source URL: <https://www.pro.novartis.com/au-en/eaaci-2025>